Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Sep;127(10):1217-1225.
doi: 10.1111/1471-0528.16239. Epub 2020 Apr 29.

Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial

H T Wolf  1 , J Brok  2 , T B Henriksen  3   4 , G Greisen  5 , J D Salvig  6 , O Pryds  7 , M Hedegaard  8   9 , T Weber  1 , H K Hegaard  9   10 , A Pinborg  1   11 , L D Huusom  1 ; MASP research group
Collaborators, Affiliations
Randomized Controlled Trial

Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial

H T Wolf et al. BJOG. 2020 Sep.

Abstract

Objective: To study the effect of antenatal magnesium sulphate (MgSO4 ) on cerebral palsy (CP) in a manner that also provides adequate power for a linked trial sequential analysis.

Design: Double-blind, randomised, placebo-controlled, multi-centre trial.

Setting: Fourteen Danish obstetric departments.

Population: In total, 560 pregnant women at risk for preterm delivery before 32 weeks of gestation were randomised from December 2011 to January 2018. Those women gave birth to 680 children.

Methods: Women were randomised to receive either a loading dose of 5 g MgSO4 followed by 1 g/hour or a placebo in identical volumes. The children were followed up at a corrected age of 18 months or older with a review of their medical charts and with the Ages and Stages Questionnaire.

Main outcome measure: The primary outcome measure was moderate to severe CP. Secondary outcomes included mortality, neonatal morbidity, blindness and mild CP.

Results: The crude rates of moderate to severe CP in the MgSO4 group and the placebo group were 2.0% and 3.3%, respectively. The adjusted odds of moderate to severe CP were lower in the MgSO4 group than in the placebo group (odds ratio 0.61; 95% CI 0.23-1.65).

Conclusions: Antenatal MgSO4 before 32 weeks of gestation decreases the likelihood of moderate to severe CP; these results are entirely consistent with other randomised evidence summarised in the linked trial sequential analysis.

Tweetable abstract: Antenatal magnesium sulphate may decrease the risk of moderate to severe cerebral palsy in children born before 32 weeks of gestation.

Keywords: Cerebral palsy; MgSO4; magnesium sulphate; mortality; neonatal morbidity; neuroprotection; preterm birth.

PubMed Disclaimer

Comment in

References

    1. LiuL, JohnsonHL, CousensS, PerinJ, ScottS, LawnJE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet2012;379:2151-61.
    1. ZeitlinJ, MortensenL, CuttiniM, LackN, NijhuisJ, HaidingerG, et al. Declines in stillbirth and neonatal mortality rates in Europe between 2004 and 2010: results from the Euro-Peristat project. J Epidemiol Community Health2016;70:609-15.
    1. RoseAT, PatelRM. A critical analysis of risk factors for necrotizing enterocolitis. Semin Fetal Neonatal Med2018;23:374-9.
    1. PrianteE, MoschinoL, MardeganV, ManzoniP, SalvadoriS, BaraldiE. Respiratory outcome after preterm birth: a long and difficult journey. Am J Perinatol2016;33:1040-2.
    1. MarlowN, WolkeD, BracewellMA, SamaraM, EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med2005;352:9-19.

Publication types